Martin D. Chapman, PhD is founder, President, and CEO of Indoor Biotechnologies, an immunodiagnostics and biotechnology company  whose biological products are used to measure allergen exposure and allergen molecules for research and diagnostics. The company also manufactures purified allergens for research and diagnostic use, and provides contract research services. The company’s clients include academic and government researchers, Fortune 500 companies, the indoor air quality industry, allergy vaccine manufacturers, and the biopharmaceutical industry.

Dr. Chapman was formerly Professor of Medicine and Microbiology at the University of Virginia and a member of the UVA Asthma and Allergic Diseases Center. He is a Fellow of the American Academy of Allergy, Asthma and Immunology, and has served as a consultant to the U.S. National Institutes of Health, the Environmental Protection Agency, and numerous biotechnology and environmental products companies.

Featuring

• 

  Conversation: Funding Mobile Health - insights from local...